cardiology
Heart Failure

Modest gain from milrinone in HFpEF pilot study

The inotropic and vasodilator drug milrinone, in an extended-release oral formulation, appears to improve quality of life and be well tolerated in patients with HFpEF, Australian research shows. A pilot study at the Alfred Hospital randomised 23 patients with symptomatic HFpEF to either the phosphodiesterase type III (PDE3) inhibitor or placebo. Predominantly a safety study, ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic